Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Cardiology · Heart Failure with Reduced Ejection Fraction

What Are Target Doses for Heart Failure Medicines?

At a Glance

For heart failure with reduced ejection fraction, guideline target doses include one Pillar 1 medicine, a beta-blocker, an MRA, and an SGLT2 inhibitor. Doctors start low and increase doses toward the highest level you can safely tolerate while checking blood pressure, kidney function, and potassium.

The “target dose” for a heart failure medication is the dose that was proven in major clinical trials to reduce hospitalizations and improve survival. For congestive heart failure with reduced ejection fraction (HFrEF—meaning the heart pumps out less blood than normal), the goal is to use four specific classes of medications. However, there is no single “perfect” dose for everyone. Your care team will start you on a low dose and gradually increase it, aiming for guideline targets, but the practical goal is the highest dose your body can safely tolerate [1][2].

The Four Foundational Pillars of HFrEF Therapy

Guidelines recommend combining four classes of medications early in your treatment, rather than waiting months to maximize one drug before starting another [3][4]. You may also take a loop diuretic (“fluid pill”) to relieve congestion and swelling, but loop diuretics are not one of the four mortality-reducing pillars [5].

Important safety note: You will take one medication from Pillar 1, not all three. If you are switching from an ACE inhibitor to an ARNI, you must wait a full 36 hours between your last ACE inhibitor pill and your first ARNI pill to prevent a dangerous allergic reaction called angioedema (severe facial or airway swelling) [6].

Guideline Target Doses

Note: These are guideline targets for adult HFrEF, not self-dosing instructions [2]. Your ideal dose may be lower depending on your blood pressure, heart rate, kidney function, potassium, age, and stability.

  • Pillar 1: ARNI, ACE Inhibitor, or ARB. These relax blood vessels and reduce strain on the heart.
    • ARNI (sacubitril/valsartan): Target is 97/103 mg twice daily (the tablet contains two component strengths) [7].
    • ACE Inhibitor (e.g., enalapril): Target is 10 mg twice daily [8].
  • Pillar 2: Beta-Blockers. These block harmful stress hormones and safely lower your heart rate so the heart can fill properly.
    • Metoprolol succinate (extended-release): Target is commonly 200 mg once daily [2].
    • Carvedilol: Target is commonly 25 mg twice daily (or 50 mg twice daily if over 85 kg) [2].
    • Bisoprolol: Target is 10 mg once daily [9].
  • Pillar 3: MRAs (Mineralocorticoid Receptor Antagonists). These block aldosterone, a hormone that causes scarring and fluid buildup.
    • Spironolactone: Target is 25 to 50 mg once daily [2]. (Note: Spironolactone can sometimes cause breast tenderness or enlargement).
    • Eplerenone: Target is 50 mg once daily [2].
  • Pillar 4: SGLT2 Inhibitors. These help the body remove excess sugar and fluid, strongly protecting the heart and kidneys.
    • Dapagliflozin or Empagliflozin: Given at a fixed dose of 10 mg once daily, so no dose increases are usually needed [9][10]. (Risks include genital infections, dehydration, and rare ketoacidosis).

How Titration Works (Starting Low and Going Slow)

Because starting at high doses can cause low blood pressure, slow heart rate, or kidney issues, doctors use a step-by-step process called titration. They will start you at a low dose and increase it at appropriate intervals—often every few weeks [11][12].

During titration, your care team will schedule follow-up labs and monitor:

  • Blood pressure and heart rate: To ensure medications don’t cause dangerous drops, which can lead to dizziness or fainting [13][5].
  • Kidney function (eGFR): Your eGFR (estimated glomerular filtration rate) measures how well your kidneys filter waste. A modest dip in eGFR can occur with Pillar 1 or 4 medicines, but a large drop requires medical review [14].
  • Potassium levels: MRAs and Pillar 1 medications can increase potassium in your blood (hyperkalemia) [9]. Severe hyperkalemia is dangerous [15]. To safely start MRAs, your eGFR is typically required to be above 30 and your potassium below 5.0 mEq/L [9][16].

What If You Cannot Reach the Target Dose?

If you experience fatigue, dizziness, or abnormal lab results, do not panic. Not reaching the textbook target does not mean your treatment has failed.

  • Any tolerated dose helps: Combining partial doses of all four foundational classes provides significant, proven benefits for your heart and is preferred over maximizing just one or two classes [1][17].
  • Flexible sequencing: If you develop a slow heart rate (bradycardia) or kidney issues, your doctor can safely change the order or priority of your medications [18][4].
  • Do not change doses on your own: Changing your heart medications or your fluid pill (diuretic) without medical guidance can worsen swelling or breathlessness [5]. Always prompt a medical review rather than making unsupervised dose changes.

When to Seek Immediate Medical Help

Do not simply wait for your body to adjust to severe side effects. Seek urgent or emergency care if you experience:

  • Swelling of your face, lips, or throat (angioedema) [6].
  • Fainting, severe dizziness, or confusion.
  • Severe or rapidly worsening breathlessness, or chest pain.
  • A markedly slow or irregular heartbeat.
  • A significant drop in urination.

Call your doctor the same day if you have repeated vomiting or diarrhea, a major change in blood pressure, rapid weight gain, or new swelling, as you may be dehydrated or retaining fluid, which affects your kidney function and medication safety.

Common questions in this guide

What does a target dose mean for a heart failure medicine?
A target dose is the amount used in major clinical trials that reduced hospitalizations and improved survival for people with heart failure with reduced ejection fraction. It is a treatment goal, not a dose to start or change on your own. Your clinician will work toward the highest dose you can safely tolerate.
What are the usual target doses for the main HFrEF medicines?
Common guideline targets include sacubitril/valsartan 97/103 mg twice daily, metoprolol succinate 200 mg once daily, carvedilol 25 mg twice daily, spironolactone 25 to 50 mg once daily, eplerenone 50 mg once daily, and dapagliflozin or empagliflozin 10 mg once daily. Enalapril is one example of an ACE inhibitor with a 10 mg twice-daily target. The appropriate medicine and dose depend on your blood pressure, heart rate, kidney function, potassium level, and overall stability.
Should I take an ARNI, an ACE inhibitor, and an ARB together?
No. Pillar 1 uses one of these options, not all three at the same time. If you change from an ACE inhibitor to sacubitril/valsartan, you need a full 36-hour gap between the last ACE inhibitor dose and the first ARNI dose to reduce the risk of severe facial or airway swelling.
How do doctors safely increase heart failure medicine doses?
Doctors usually start with a low dose and increase it gradually, often every few weeks. They check blood pressure, heart rate, kidney function, and potassium during titration. The goal is the highest dose your body can safely tolerate, which may be below the textbook target.
What happens if I cannot reach the target dose?
Not reaching the textbook target does not mean treatment has failed. Taking tolerated doses from all four foundational medication classes can provide important benefit and may be better than taking a maximum dose of only one or two classes. Do not reduce, stop, or increase a heart failure medicine or diuretic without medical guidance.
When should I get urgent help after changing a heart failure medicine?
Seek urgent or emergency care for swelling of the face, lips, or throat; fainting; severe dizziness or confusion; severe or rapidly worsening breathlessness; chest pain; a markedly slow or irregular heartbeat; or a major decrease in urination. Contact your doctor the same day for repeated vomiting or diarrhea, a major blood-pressure change, rapid weight gain, or new swelling.

Get notified when new evidence is published on congestive heart failure.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?

    Hu JR, Schwann AN, Tan JW, et al.

    Heart failure clinics 2024; (20(4)):373-386 doi:10.1016/j.hfc.2024.06.004.

    PMID: 39216923
  2. 2

    Heart failure with reduced ejection fraction.

    Cannata A, Crespo-Leiro MG, Bromage DI, et al.

    Lancet (London, England) 2026; (407(10527)):529-542 doi:10.1016/S0140-6736(25)01851-3.

    PMID: 41319669
  3. 3

    Expert Opinion on Optimising Guideline-Directed Medical Therapy and Expanding the Role of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) for Heart Failure Management in India.

    Pandey BP, Ray S, Kumar S, et al.

    Cureus 2026; (18(4)):e107772 doi:10.7759/cureus.107772.

    PMID: 42211603
  4. 4

    Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts.

    Girerd N, Leclercq C, Hanon O, et al.

    Revista espanola de cardiologia (English ed.) 2023; (76(10)):813-820 doi:10.1016/j.rec.2023.03.005.

    PMID: 36914024
  5. 5

    Tailoring guideline-directed medical therapy in heart failure with reduced ejection fraction: A practical guide.

    Kapłon-Cieślicka A, Vardas P, Grabowski M, Lelonek M

    Kardiologia polska 2023; doi:10.33963/v.kp.97248.

    PMID: 37660390
  6. 6

    Inpatient Initiation of Sacubitril/Valsartan.

    Chilbert MR, Rogers KC, Ciriello DN, et al.

    The Annals of pharmacotherapy 2021; (55(4)):480-495 doi:10.1177/1060028020947446.

    PMID: 32741197
  7. 7

    Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.

    Wachter R, Senni M, Belohlavek J, et al.

    European journal of heart failure 2019; (21(8)):998-1007 doi:10.1002/ejhf.1498.

    PMID: 31134724
  8. 8

    Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.

    Velazquez EJ, Morrow DA, DeVore AD, et al.

    The New England journal of medicine 2019; (380(6)):539-548 doi:10.1056/NEJMoa1812851.

    PMID: 30415601
  9. 9

    Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review.

    Barry AR

    CJC open 2022; (4(9)):802-809 doi:10.1016/j.cjco.2022.06.007.

    PMID: 36148258
  10. 10

    Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study).

    Leszek P, Csanádi Z, Gruev I, et al.

    ESC heart failure 2026; (13(3)) doi:10.1093/eschf/xvag085.

    PMID: 41858299
  11. 11

    Remote monitoring titration clinic to implement guideline-directed therapy for heart failure patients with reduced ejection fraction: a pilot quality-improvement intervention.

    Romero E, Yala S, Sellers-Porter C, et al.

    Frontiers in cardiovascular medicine 2023; (10()):1202615 doi:10.3389/fcvm.2023.1202615.

    PMID: 37404735
  12. 12

    Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.

    Greene SJ, Fonarow GC, DeVore AD, et al.

    Journal of the American College of Cardiology 2019; (73(19)):2365-2383 doi:10.1016/j.jacc.2019.02.015.

    PMID: 30844480
  13. 13

    Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

    Blood AJ, Fischer CM, Fera LE, et al.

    Clinical cardiology 2020; (43(1)):4-13 doi:10.1002/clc.23291.

    PMID: 31725920
  14. 14

    Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.

    Beldhuis IE, Lam CSP, Testani JM, et al.

    Circulation 2022; (145(9)):693-712 doi:10.1161/CIRCULATIONAHA.121.052792.

    PMID: 35226558
  15. 15

    European Journal of Heart Failure International Expert Position Paper-Utilization, optimization, and clinical benefits of steroidal mineralocorticoid receptor antagonists in heart failure with a reduced ejection fraction.

    Böhm M, Abdullakutty J, Bauersachs J, et al.

    European journal of heart failure 2026; (28(3)):513-534 doi:10.1093/ejhf/xuag106.

    PMID: 41955577
  16. 16

    Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.

    Ferreira JP, Rossignol P, Machu JL, et al.

    European journal of heart failure 2017; (19(10)):1284-1293 doi:10.1002/ejhf.900.

    PMID: 28580625
  17. 17

    Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization.

    Dixit NM, Shah S, Ziaeian B, et al.

    US cardiology 2021; (15()):e07 doi:10.15420/usc.2020.29.

    PMID: 39720493
  18. 18

    Drug Layering in Heart Failure: Phenotype-Guided Initiation.

    Rosano GMC, Allen LA, Abdin A, et al.

    JACC. Heart failure 2021; (9(11)):775-783 doi:10.1016/j.jchf.2021.06.011.

    PMID: 34627725

This page is for informational purposes only and does not constitute medical advice or instructions to change your heart-failure medicines. Your care team should set and monitor your dose based on your health and laboratory results.